5.54
+0.24(+4.53%)
Currency In USD
| Previous Close | 5.3 |
| Open | 5.3 |
| Day High | 5.67 |
| Day Low | 5.24 |
| 52-Week High | 7.63 |
| 52-Week Low | 3.38 |
| Volume | 7.82M |
| Average Volume | 4.65M |
| Market Cap | 1.7B |
| PE | 50.36 |
| EPS | 0.11 |
| Moving Average 50 Days | 5.23 |
| Moving Average 200 Days | 4.8 |
| Change | 0.24 |
If you invested $1000 in MannKind Corporation (MNKD) 10 years ago, it would be worth $334.74 as of October 30, 2025 at a share price of $5.54. Whereas If you bought $1000 worth of MannKind Corporation (MNKD) shares 5 years ago, it would be worth $2,756.22 as of October 30, 2025 at a share price of $5.54.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
MannKind Corporation to Hold 2025 Third Quarter Financial Results Conference Call on November 5, 2025
GlobeNewswire Inc.
12 hours ago
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), announced today that its third quarter 2025 financial results will be released before the market opens on November 5, 2025. MannKind
MannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years Living with Diabetes
GlobeNewswire Inc.
Oct 13, 2025 12:05 PM GMT
If approved, it would be the first needle-free insulin option for pediatric patients in 100+ years of insulin therapysBLA submission based on data from the Phase 3 INHALE-1 study PDUFA target action date of May 29, 2026 WESTLAKE VILLAGE, Calif. and D
MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care
GlobeNewswire Inc.
Oct 07, 2025 1:00 PM GMT
DANBURY, Conn. and BURLINGTON, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) successfully completed the previously announced acquisition of scPharmaceuticals Inc. The acquisition of scPharmaceuticals is expected to di